|
T3184 |
Kevetrin hydrochloride
|
Thioureidobutyronitrile HCl,thioureido butyronitrile hydrochloride,4-Isothioureidobutyronitrile hydrochloride |
Mdm2
,
p53
|
|
Kevetrin hydrochloride (4-Isothioureidobutyronitrile hydrochloride) is a small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity. |
|
T31221 |
DBRD9
|
dBRD-9,dBRD 9 |
PROTACs
|
|
dBRD9 is a PROTAC. dBRD9 is a double-acting molecule, partially containing Bromodomain-containing protein 9 (BRD9), ligand that recruits the cereblon E3 ubiquitin ligase. Ligand that recruits the cereblon E3 ubiquitin li... |
|
T31221L |
DBRD9 HCl
|
dBRD9 HCl(2170679-45-3 Free base) |
Epigenetic Reader Domain
|
|
dBRD9 HCl is a PROTAC composed of the BRD9 inhibitor BI 7273 conjugated to the cereblon E3 ligase ligand pomalidomide . dBRD9 HCl is a potent and selective degrader of BRD9 (IC50 = 56.6 nM in MOLM-13 cells). dBRD9 HCl do... |
|
T81128 |
Sontigidomide
|
|
|
|
Sontigidomide (Compound 5) is an antineoplastic agent that demonstrates over 80% inhibition of MOLM-13 cell proliferation at a concentration of 1 μM after 3 days [1]. |
|
T81108 |
SR-1114
|
|
PROTACs
|
|
SR-1114, a first-in-class PROTAC ENL degrader, induces rapid CRBN-dependent ENL degradation with DC50 values of 150 nM in MV4;11 cells, 311 nM in MOLM-13 cells, and 1.65 μM in OCI/AML-2 cells [1]. |
|
T79596 |
FLT3-IN-20
|
|
|
|
FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor, demonstrating IC50 values of 1 nM for FLT3-D835Y and 4 nM for FLT3-ITD. It exhibits anti-proliferative effects on FLT3-ITD-positive AML cell lines, with IC50s of 7 nM... |
|
T24045 |
ESM156
|
eSM 156,eSM-156 |
|
|
eSM156 is an effective FLT3 inhibitor. It has high antiproliferative activity against acute myeloid leukemia (AML) cells. eSM156 has IC50 (FLT3) = 1.4 nM; EC50 (MV4-11cells) = 150 nM; EC50 (MOLM-13 cells) = 40 nM. |
|
T81806 |
METTL3-IN-5
|
|
|
|
METTL3-IN-5 (Compound 13) serves as an inhibitor of METTL3 and demonstrates efficacy in suppressing MOLM-13 cell growth with an IC50 of less than 2 μM. Moreover, it exhibits minimal hERG inhibitory activity, with an IC50... |
|
T40168 |
DHODH-IN-16
|
|
Dehydrogenase
|
|
DHODH-IN-16 is an effective inhibitor of dihydroorotate dehydrogenase (DHODH, IC50 = 0.396 nM for human). |
|
T61768 |
FY-56
|
|
|
|
FY-56, a highly potent and selective inhibitor of LSD1/KDM1A with an IC50 value of 42 nM, demonstrates significant selectivity over MAO-A/B. This compound effectively induces differentiation in MOLM-13 and MV4-11 cells, ... |
|
T37447 |
UZH1
|
UZH1 |
|
|
UZH1 is a racemate of UZH1a and UZH1b. UZH1a is a potent and selective METTL3 inhibitor, with an IC50 of 280 nM. UZH1b (IC50=28 μM) is essentially inactive. UZH1 can be used for epitranscriptomic modulation of cellular p... |
|
T73637 |
Dot1L-IN-1 TFA
|
|
|
|
Dot1L-IN-1 TFA is a potent and selective Dot1L inhibitor, characterized by a K i of 2 pM and an IC 50 of <0.1 nM. It effectively inhibits H3K79 dimethylation (IC 50 =3 nM) and suppresses the HoxA9 promoter activity (IC 5... |
|
T17878 |
Lenalidomide-C4-NH2 hydrochloride
|
Cereblon ligand 1 hydrochloride,E3 ligase Ligand-Linker Conjugates 32 hydrochloride |
Others
|
|
Lenalidomide-C4-NH2 hydrochloride is a Cereblon ligand derived from Lenalidomide. It serves as a recruiting agent for the CRBN protein. The compound, known as PROTAC (Compound 24), can be formed by linking Lenalidomide-C... |
|
T61005 |
K783-0308
|
|
|
|
K783-0308 is a potent and selective MNK2 and FLT3 dual inhibitor with IC 50 values of 406 and 680 nM, respectively. K783-0308 promotes the apoptosis and cell cycle arrests in the G0/G1 phase of acute myeloid leukemia (AM... |
|
T71973 |
Gilteritinib hemifumarate
|
ASP2215 hemifumarate |
FLT
,
TAM Receptor
|
|
Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of relapsed or refractory FLT3 mutant AML. |
|
T69629 |
M‑89 MLL inhibitor
|
|
|
|
M‑89 is a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein−Protein Interaction (Kd = 1.4 nM; IC50 = 25nM). M-89 binds to menin with a Kd value of 1.4 nM and effectively engages cellular men... |
|
T62112 |
CDK8-IN-6
|
|
|
|
CDK8-IN-6 (compound 9) is a potent inhibitor of cyclin-dependent kinase 8 (CDK8) (Kd: 13 nM), CDK8-IN-6 showed potential research value in AML cancers. |
|
T10464L |
Atuveciclib Racemate
|
BAY-1143572 Racemate |
CDK
|
|
Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib, which is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM. |
|
T2243 |
Serdemetan
|
JNJ-26854165 |
Apoptosis
,
Mdm2
,
E1/E2/E3 Enzyme
,
p53
|
|
Serdemetan (JNJ-26854165) is an orally bioavailable HDM2 antagonist with potential antineoplastic activity. |
|
T70779 |
BPR1J-340
|
|
|
|
BPR1J-340 is a potent and selective FLT3 inhibitor with potential anticancer activity. BPR1J-340 was identified as a novel potent FLT3 inhibitor by biochemical kinase activity (IC50 approximately 25 nM) and cellular prol... |
|
T4261 |
BPR1J-097 hydrochloride (1327167-19-0(free base))
|
|
FLT
|
|
BPR1J-097, a new-type small molecule FLT-3 inhibitor(IC50=11±7 nM), is with great anti-tumor activities in vivo. |
|
T62354 |
CDK8-IN-7
|
|
|
|
CDK8-IN-7 (compound 12) is a potent and selective inhibitor of cyclin-dependent kinase 8 (CDK8) (Kd: 3.5 nM). CDK8-IN-7 has shown potential for AML-cancer research. |
|
T61202 |
TDO-IN-1
|
|
Others
|
|
TDO-IN-1 is an orally active, potent, and selective inhibitor of tryptophan 2,3-dioxygenase (TDO), which inhibits indoleamine-2,3-dioxygenase.TDO-IN-1 has antitumor activity and is able to act by reversing local immune t... |
|
T39937 |
M-808
|
|
|
|
M-808 is a potent and efficacious covalent inhibitor, targeting the interaction between Menin and MLL. It demonstrates a high binding affinity with an IC50 value of 2.6 nM. |
